• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

叉头框蛋白 P3 在 IFNγ 介导的 PD-L1 表达和膀胱癌上皮间质转化中的作用。

Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition.

机构信息

Department of Urology, University of California, Los Angeles, California.

Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, California.

出版信息

Cancer Res Commun. 2024 Aug 1;4(8):2228-2241. doi: 10.1158/2767-9764.CRC-23-0493.

DOI:10.1158/2767-9764.CRC-23-0493
PMID:39099201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11345674/
Abstract

UNLABELLED

Antagonism of the PD-1/PD-L1 axis is a critical therapeutic strategy for patients with advanced bladder cancer. IFNγ functions as a key regulator of PD-L1 in both immune as well as cancer cells. Forkhead box P3 (FOXP3) is a transcription factor synonymous in T regulatory cell function but with increasingly described functions in cancer cells. Here, we investigated the relationship between FOXP3 and PD-L1 in bladder cancer. We showed that FOXP3 is critical in the ability for IFNγ to activate PD-L1 in bladder cancer cells. FOXP3 can bind to the PD-L1 promoter and induces a gene program that leads to regulation of multiple immune-related genes and genes involved in epithelial-to-mesenchymal transition (EMT). Using in vitro and in vivo human and murine models, we showed that FOXP3 can influence bladder cancer EMT as well as promote cancer metastases. Furthermore, FOXP3 may be a convergent factor for multiple activators of PD-L1, including the chemotherapeutic drug cisplatin.

SIGNIFICANCE

Historically a key transcription factor driving T regulatory cell function, FOXP3 has an increasingly recognized role in cancer cells. In bladder cancer, we defined a novel mechanism whereby FOXP3 mediates the activation of the immune checkpoint PD-L1 by the cytokine IFNγ. We also showed that FOXP3 induces other immune checkpoints as well as genes involved in EMT, promoting immune resistance and cancer metastases.

摘要

未标记

PD-1/PD-L1 轴的拮抗作用是晚期膀胱癌患者的关键治疗策略。IFNγ 作为 PD-L1 在免疫细胞和癌细胞中的关键调节因子发挥作用。叉头框 P3(FOXP3)是 T 调节细胞功能的转录因子,但在癌细胞中越来越多地描述了其功能。在这里,我们研究了膀胱癌中 FOXP3 和 PD-L1 之间的关系。我们表明,FOXP3 对于 IFNγ 在膀胱癌细胞中激活 PD-L1 的能力至关重要。FOXP3 可以结合 PD-L1 启动子,并诱导导致调节多个免疫相关基因和上皮-间充质转化(EMT)相关基因的基因程序。使用体外和体内的人源和鼠源模型,我们表明 FOXP3 可以影响膀胱癌 EMT 并促进癌症转移。此外,FOXP3 可能是 PD-L1 的多个激活剂的收敛因子,包括化疗药物顺铂。

意义

FOXP3 历史上是驱动 T 调节细胞功能的关键转录因子,在癌细胞中具有越来越被认可的作用。在膀胱癌中,我们定义了一种新的机制,即 FOXP3 通过细胞因子 IFNγ 介导免疫检查点 PD-L1 的激活。我们还表明,FOXP3 诱导其他免疫检查点以及参与 EMT 的基因,促进免疫抵抗和癌症转移。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/3174d0e9a8f5/crc-23-0493_f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/b59dc00d40ae/crc-23-0493_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/ce4d648d322c/crc-23-0493_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/259f523de062/crc-23-0493_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/d460403fc29a/crc-23-0493_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/93f997555d86/crc-23-0493_f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/3174d0e9a8f5/crc-23-0493_f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/b59dc00d40ae/crc-23-0493_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/ce4d648d322c/crc-23-0493_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/259f523de062/crc-23-0493_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/d460403fc29a/crc-23-0493_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/93f997555d86/crc-23-0493_f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b7/11345674/3174d0e9a8f5/crc-23-0493_f6.jpg

相似文献

1
Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition.叉头框蛋白 P3 在 IFNγ 介导的 PD-L1 表达和膀胱癌上皮间质转化中的作用。
Cancer Res Commun. 2024 Aug 1;4(8):2228-2241. doi: 10.1158/2767-9764.CRC-23-0493.
2
PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.PD-L1 是胰腺导管腺癌(PDAC)中癌症 FOXP3 的直接靶点,联合使用抗 PD-L1 和 CCL5 抗体的免疫疗法对 PDAC 的治疗有效。
Signal Transduct Target Ther. 2020 Apr 17;5(1):38. doi: 10.1038/s41392-020-0144-8.
3
IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.IFN-γ 促进胰腺癌中的上皮-间充质转化和 PD-L1 的表达。
J Surg Res. 2019 Aug;240:115-123. doi: 10.1016/j.jss.2019.02.038. Epub 2019 Mar 27.
4
Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma.程序性死亡配体1在肿瘤浸润前沿的表达与食管鳞状细胞癌的上皮-间质转化及不良预后相关。
Cancer Sci. 2017 Jun;108(6):1119-1127. doi: 10.1111/cas.13237. Epub 2017 May 25.
5
The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.幽门螺杆菌毒力因子与 PD1:PD-L1 免疫检查点抑制剂在胃癌进展中的相互作用。
Immunol Lett. 2021 Nov;239:1-11. doi: 10.1016/j.imlet.2021.06.009. Epub 2021 Aug 5.
6
Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.基于微环境免疫类型和程序性死亡受体配体1(PD-L1)的基因组分层,用于定制膀胱癌的治疗策略。
BMC Cancer. 2021 May 31;21(1):646. doi: 10.1186/s12885-021-08350-1.
7
PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer.程序性死亡配体1(PD-L1)表达促进人食管癌上皮-间质转化
Cell Physiol Biochem. 2017;42(6):2267-2280. doi: 10.1159/000480000. Epub 2017 Aug 17.
8
IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.干扰素 γ 诱导的卵巢癌细胞程序性死亡配体 1 表达受 JAK1、STAT1 和 IRF1 信号通路调控。
Cell Signal. 2022 Sep;97:110400. doi: 10.1016/j.cellsig.2022.110400. Epub 2022 Jul 9.
9
Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1/SOX10 regulatory axis.在黑色素瘤细胞模型中,TP53 基因状态与 PD-L1 蛋白水平呈负相关,这取决于一个 IRF1/SOX10 调节轴。
Cell Mol Biol Lett. 2024 Sep 5;29(1):117. doi: 10.1186/s11658-024-00637-y.
10
PD-L1 knockdown suppresses vasculogenic mimicry of non-small cell lung cancer by modulating ZEB1-triggered EMT.PD-L1 敲低通过调节 ZEB1 触发的 EMT 抑制非小细胞肺癌的血管生成拟态。
BMC Cancer. 2024 May 23;24(1):633. doi: 10.1186/s12885-024-12390-8.

本文引用的文献

1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.恩福妥单抗Vedotin 联合帕博利珠单抗治疗未经治疗的晚期尿路上皮癌。
N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117.
2
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.纳武利尤单抗联合吉西他滨-顺铂治疗晚期尿路上皮癌。
N Engl J Med. 2023 Nov 9;389(19):1778-1789. doi: 10.1056/NEJMoa2309863. Epub 2023 Oct 22.
3
The JAK-STAT pathway at 30: Much learned, much more to do.JAK-STAT 通路 30 年:学无止境,任重道远。
Cell. 2022 Oct 13;185(21):3857-3876. doi: 10.1016/j.cell.2022.09.023.
4
ICAM1 promotes bone metastasis via integrin-mediated TGF-β/EMT signaling in triple-negative breast cancer.ICAM1 通过整合素介导的 TGF-β/EMT 信号促进三阴性乳腺癌的骨转移。
Cancer Sci. 2022 Nov;113(11):3751-3765. doi: 10.1111/cas.15532. Epub 2022 Aug 26.
5
FOXP3 exon 2 controls T stability and autoimmunity.FOXP3 外显子 2 控制 T 细胞稳定性和自身免疫。
Sci Immunol. 2022 Jun 24;7(72):eabo5407. doi: 10.1126/sciimmunol.abo5407.
6
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.癌症中调节程序性死亡受体配体1(PD-L1)表达的机制及新型小分子疗法的相关机遇
Nat Rev Clin Oncol. 2022 May;19(5):287-305. doi: 10.1038/s41571-022-00601-9. Epub 2022 Feb 7.
7
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
8
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.长链非编码 RNA 和 circRNA 在癌症免疫治疗中 PD-1/PD-L1 通路的作用。
Mol Cancer. 2021 Sep 8;20(1):116. doi: 10.1186/s12943-021-01406-7.
9
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.癌症免疫疗法更新:FDA 批准的检查点抑制剂和伴随诊断。
AAPS J. 2021 Mar 7;23(2):39. doi: 10.1208/s12248-021-00574-0.
10
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.用于治疗膀胱癌的免疫检查点抑制剂
Cancers (Basel). 2021 Jan 3;13(1):131. doi: 10.3390/cancers13010131.